Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 1 for:    NCT01816113
Previous Study | Return to List | Next Study

Phase Ia Study of ChAd63/MVA PvDBP

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01816113
Recruitment Status : Completed
First Posted : March 21, 2013
Last Update Posted : May 8, 2017
Sponsor:
Information provided by (Responsible Party):
University of Oxford

Brief Summary:
This is an open label phase Ia study, to assess the safety of two novel malaria vaccines, ChAd63 PvDBP, with or without MVA PvDBP. Heterologous prime-boost with ChAd63-MVA is, to our knowledge, one of the most potent T cell-inducing subunit vaccine regimens which can importantly also induce antibodies. Previous clinical trials using this regimen expressing ME-TRAP, AMA1 & MSP1, have shown that administering ChAd63 as a prime followed 8 weeks later by MVA as a boost is a very immunogenic schedule (32-34). For this reason, and to provide comparability with previous ChAd63-MVA trials, we propose to use a similar administration schedule.

Condition or disease Intervention/treatment Phase
Malaria Plasmodium Vivax Biological: ChAd63 PvDBP 5 x 10^9 Biological: ChAd63 PvDBP 5 x 10^10 Biological: MVA PvDBP 1 x 10^8 Biological: MVA PvDBP 2 x 10^8 Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 24 participants
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Prevention
Official Title: A Phase Ia Clinical Trial to Assess the Safety and Immunogenicity of New Plasmodium Vivax Malaria Vaccine Candidates ChAd63 PvDBP Alone and With MVA PvDBP
Study Start Date : April 2013
Actual Primary Completion Date : July 2014
Actual Study Completion Date : July 2014

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Malaria

Arm Intervention/treatment
Experimental: Group 1
4 volunteers; 1 dose of ChAd63 PvDBP 5 x 10^9 vp intramuscularly
Biological: ChAd63 PvDBP 5 x 10^9
1 dose of ChAd63 PvDBP 5 x 10^9 vp intramuscularly

Experimental: Group 2A
4 volunteers; 1 dose of ChAd63 PvDBP 5 x 10^10 vp intramuscularly
Biological: ChAd63 PvDBP 5 x 10^10
1 dose of ChAd63 PvDBP 5 x 10^10 vp intramuscularly

Experimental: Group 2B
8 volunteers; 1 dose of ChAd63 PvDBP 5 x 10^10 vp intramuscularly and 1 dose MVA PvDBP 1 x 10^8 pfu 8 weeks later intramuscularly
Biological: ChAd63 PvDBP 5 x 10^10
1 dose of ChAd63 PvDBP 5 x 10^10 vp intramuscularly

Biological: MVA PvDBP 1 x 10^8
1 dose MVA PvDBP 1 x 108 pfu 8 weeks later intramuscularly

Experimental: Group 2C
8 volunteers; 1 dose of ChAd63 PvDBP 5 x 10^10 vp intramuscularly and 1 dose MVA PvDBP 2 x 10^8 pfu 8 weeks later intramuscularly
Biological: ChAd63 PvDBP 5 x 10^10
1 dose of ChAd63 PvDBP 5 x 10^10 vp intramuscularly

Biological: MVA PvDBP 2 x 10^8
1 dose MVA PvDBP 2 x 108 pfu 8 weeks later intramuscularly




Primary Outcome Measures :
  1. The safety in healthy volunteers of two new candidate malaria vaccines, ChAd63 PvDBP administered alone, and with MVA PvDBP, in a prime-boost regime. [ Time Frame: Up to 20 weeks post first vaccination ]
    To assess the safety of ChAd63 PvDBP when administered alone and in heterologous prime-boost with MVA PvDBP. Safety will be assessed by the frequency, incidence and nature of adverse events and serious adverse events arising during the study as well as abnormalities in Hematology and Biochemistry lab tests.


Secondary Outcome Measures :
  1. The humoral and cellular immunogenicity of ChAd63 PvDBP, when administered to healthy volunteers alone and with MVA PvDBP. [ Time Frame: U to 20 weeks post first vaccination. ]

    PvDBP_RII-specific immunogenicity will be assessed by a variety of immunological assays. These may include ex vivo ELISpot assays for interferon gamma and flow cytometry assays, as well as antibody ELISAs. Other exploratory immunological assays including cytokine analysis, antibody assays, anti-adenovirus antibodies, DNA analysis of genetic polymorphisms potentially relevant to vaccine immunogenicity and gene expression studies amongst others may be performed at the discretion of the investigators.

    Other exploratory immunology may be carried out in collaboration with other specialist labs, including labs outside of Europe. This would involve transfer of serum/plasma, but samples will be anonymised. Volunteers will be consented beforehand.




Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 50 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Healthy adults aged 18 to 50 years.
  • Able and willing (in the Investigator's opinion) to comply with all study requirements.
  • Willing to allow the investigators to discuss the volunteer's medical history with their General Practitioner.
  • For females only, willingness to practice continuous effective contraception during the study and a negative pregnancy test on the day(s) of vaccination.

Agreement to refrain from blood donation during the course of the study.

-Provide written informed consent.

Exclusion Criteria:

  • Participation in another research study involving receipt of an investigational product in the 30 days preceding enrolment, or planned use during the study period.
  • Prior receipt of an investigational malaria vaccine or any other investigational vaccine likely to impact on interpretation of the trial data.
  • Administration of immunoglobulins and/or any blood products within the three months preceding the planned administration of the vaccine candidate.
  • Any confirmed or suspected immunosuppressive or immunodeficient state, including HIV infection; asplenia; recurrent, severe infections and chronic (more than 14 days) immunosuppressant medication within the past 6 months (inhaled and topical steroids are allowed).
  • History of allergic disease or reactions likely to be exacerbated by any component of the vaccine, e.g. egg products, Kathon.
  • History of clinically significant contact dermatitis.
  • Any history of anaphylaxis in reaction to vaccination.
  • Pregnancy, lactation or willingness/intention to become pregnant during the study.
  • History of cancer (except basal cell carcinoma of the skin and cervical carcinoma in situ).
  • History of serious psychiatric condition.
  • Any other serious chronic illness requiring hospital specialist supervision.
  • Suspected or known current alcohol abuse as defined by an alcohol intake of greater than 42 units every week.
  • Suspected or known injecting drug abuse in the 5 years preceding enrolment.
  • Seropositive for hepatitis B surface antigen (HBsAg).
  • Seropositive for hepatitis C virus (antibodies to HCV) with positive PCR for hepatitis C at screening.
  • History of clinical malaria (any species).
  • Travel to a malaria endemic region during the study period or within the previous six months.
  • Any clinically significant abnormal finding on screening biochemistry or haematology blood tests or urinalysis.
  • Any other significant disease, disorder or finding which may significantly increase the risk to the volunteer because of participation in the study, affect the ability of the volunteer to participate in the study or impair interpretation of the study data.
  • Inability of the study team to contact the volunteer's GP to confirm medical history and safety to participate.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01816113


Locations
Layout table for location information
United Kingdom
Centre for Clinical Vaccinology and Tropical Medicine
Oxford, Oxfordshire, United Kingdom, OX3 7LE
Sponsors and Collaborators
University of Oxford
Investigators
Layout table for investigator information
Principal Investigator: Adrian V S Hill, MD University of Oxford

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: University of Oxford
ClinicalTrials.gov Identifier: NCT01816113     History of Changes
Other Study ID Numbers: VAC051
First Posted: March 21, 2013    Key Record Dates
Last Update Posted: May 8, 2017
Last Verified: May 2017

Keywords provided by University of Oxford:
PvDBP
Malaria
Plasmodium vivax

Additional relevant MeSH terms:
Layout table for MeSH terms
Malaria
Protozoan Infections
Parasitic Diseases